Related Experiment Video
Updated: May 16, 2025
07:56
Utilizing Time-Resolved Protein-Induced Fluorescence Enhancement to Identify Stable Local Conformations One α-Synuclein Monomer at a Time
Published on: May 30, 2021
3.1K
Using a stable protein scaffold to display peptides that bind to alpha-synuclein fibrils
Samuel Bismut1, Matthias M Schneider2, Masashi Miyasaki1
1Department of Pharmacology, University of Cambridge, Cambridge, UK.
Summary
Researchers developed a novel method to create soluble protein binders for targeting amyloid fibrils, a key feature in neurodegenerative diseases like Alzheimer's and Parkinson's. This approach uses a stable protein scaffold to display aggregation-inhibiting peptides, aiding in therapeutic development.
Area of Science:
- Biochemistry
- Neuroscience
- Protein Engineering
Background:
- Amyloid fibrils are pathological hallmarks of neurodegenerative diseases, including Alzheimer's and Parkinson's.
- Inhibiting protein aggregation and targeting aggregation-prone species are crucial therapeutic strategies.
- Hydrophobic peptides that inhibit aggregation are difficult to handle, necessitating soluble display strategies.
Purpose of the Study:
- To develop a method for displaying hydrophobic, aggregation-inhibiting peptides on a soluble protein scaffold.
- To create novel molecules that can bind to and potentially disrupt amyloid fibrils, specifically targeting alpha-synuclein.
- To facilitate the screening of peptide modulators for protein aggregation.
Main Methods:
- Grafting KLVFF-derived peptides, known to inhibit protein aggregation, onto an ultra-stable consensus-designed tetratricopeptide repeat (CTPR) protein scaffold.
- Characterizing the resulting CTPR-based proteins for their ability to bind to alpha-synuclein fibrils.
- Assessing the affinity of these novel binders.
Main Results:
- Successfully produced soluble CTPR-based proteins displaying KLVFF-derived peptides.
- Demonstrated that these engineered proteins bind to alpha-synuclein fibrils with micromolar affinity.
- Validated the CTPR scaffold as a viable platform for presenting hydrophobic peptides.
Conclusions:
- The CTPR scaffold can be effectively used to display functional peptides for targeting amyloid fibrils.
- This strategy overcomes the handling difficulties associated with hydrophobic peptides, enabling their use in therapeutic development.
- The developed method offers a promising approach for screening and designing peptide modulators of protein aggregation in neurodegenerative diseases.
